Study the Role of SHMT1 Polymorphism in Parkinson Disease Clinical Trial
Official title:
Genetic Polymorphisms of Serine Hydroxylmethyl Transferase 1 (SHMT1) in Patients With Parkinson's Disease
NCT number | NCT04706065 |
Other study ID # | aswan |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | January 31, 2021 |
Est. completion date | January 2022 |
Parkinson Disease (PD) is the most common movement disorder and represents the second most common degenerative disease of the central nervous system . SHMT has been shown to be associated with various diseases.
Status | Recruiting |
Enrollment | 80 |
Est. completion date | January 2022 |
Est. primary completion date | July 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 50 Years and older |
Eligibility | Inclusion Criteria: - Patients age = 50 years. - Patients with PD diagnosed according to the United Kingdom Parkinson's Disease Society Brain Bank (UK PDS Brain Bank diagnostic criteria) Exclusion Criteria: - Patients with parkinsonian plus syndrome - Patients with secondary parkinsonism - Patients with other chronic comorbidities (renal, hepatic, and endocrinal disturbances and chronic chest disease.) - Past and /or present history of epilepsy. - Patients with disturbed conscious level. |
Country | Name | City | State |
---|---|---|---|
Egypt | Effat abdelhady tony | Assuit |
Lead Sponsor | Collaborator |
---|---|
Assiut University | Aswan University Hospital |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | polymorphism of SHMT1gene | one year | ||
Secondary | the role of SHMT1plymorphism in pathogenesis PD | one year | ||
Secondary | Study the relationship of Shmt1 polymorphism to the severity of Parkinson disease | One year |